Eisai's Lenvima receives FDA approval for new indication

Eisai has received approval from the US Food and Drug Administration (FDA) for a new indication of its anticancer agent, Lenvima (lenvatinib mesylate), as a treatment for advanced renal cell carcinoma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news